TDOC posts narrower-than-expected Q4 loss, topping revenue estimates as international and Integrated Care strength offset BetterHelp weakness.
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc Health, Inc. (TDOC) Q4 2025 Earnings Call Transcript
Teladoc Health's shares have been crushed over the past five years. The company has sought to turn things around, but with little success so far.
TDOC heads into Q4 earnings with an improving loss outlook and rising Integrated Care EBITDA, but BetterHelp declines may weigh on revenues.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Teladoc (TDOC) reached $4.56 at the closing of the latest trading day, reflecting a -1.94% change compared to its last close.
Teladoc (TDOC) closed at $4.85 in the latest trading session, marking a -2.61% move from the prior day.
The latest trading day saw Teladoc (TDOC) settling at $5.91, representing a -6.04% change from its previous close.
Teladoc Health, Inc. (TDOC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Shares of Teladoc Health, Inc. (NYSE: TDOC - Get Free Report) have been given an average recommendation of "Hold" by the eighteen research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and five have given a buy recommendation
In the latest trading session, Teladoc (TDOC) closed at $7.57, marking a -5.38% move from the previous day.